Description
Clinical-Grade
Ostarine (Enobosarm, GTx-024, MK-2866) represents the most clinically validated SARM available—backed by completed Phase II human trials. This is pharmaceutical-grade muscle preservation with documented efficacy.
The Mechanism
Unlike non-selective androgens, Ostarine demonstrates tissue-selective activation, with high AR binding affinity, potent full agonist effects in skeletal muscle and bone, and partial agonist or antagonistic effects in prostate and seminal vesicles. Ostarine activates the ERK1/2 kinase pathway and up-regulates myogenic regulatory factors including MyoD, Myogenin, and myosin heavy chain (MyH)—the fundamental transcription factors driving muscle fiber differentiation and growth. This receptor-mediated signaling promotes protein synthesis and nitrogen retention without hepatotoxicity, a critical advantage over oral anabolic steroids.
Anabolic Capacity
Phase II clinical trials in 120 healthy subjects demonstrated dose-dependent increases in total lean body mass. More importantly, these lean mass gains translated to functional performance improvements—subjects showed 15.5% faster stair climb times and 25.5% increased power output. Animal studies confirm sustained muscle vascularization improvements and myogenic differentiation.
This is not speculation, it’s clinical validation, because the science works —
There are no reviews yet.